advertisement
Abstract #6188 Published in IGR 2-2
Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost
Lima MC; Paranhos A Jr; Salim S; Honkanen RA; Devgan L; Wand M; Gaudio AR; Shields MBJournal of Glaucoma 2000; 9: 317-321
PURPOSE: To investigate the incidence of visual significant cystoid macular edema associated with the use of latanoprost in patients with glaucoma after cataract surgery. PATIENTS AND METHODS: This was a multicenter, retrospective study of 185 patients, of whom 173 were pseudophakic (212 eyes) and 12 were aphakic (13 eyes), who were treated for glaucoma with latanoprost 0.005%. The posterior lens capsule was intact in 125 eyes, open or absent as a result of surgery in 25 eyes, and status-post-YAG capsulotomy in 75 eyes. Visual acuity was documented before and after initiating latanoprost therapy, and patients with a reduction of two or more lines on the Snellen chart were examined by fluorescein angiography for cystoid macular edema. RESULTS: Visual reduction was documented in four (2.16%) patients. Three of these four patients had cystoid macular edema, and the fourth was thought to have lost a central island of vision from glaucoma. The three patients with cystoid macular edema all had ruptured posterior capsules, requiring anterior vitrectomy, and one had had a previous episode of cystoid macular edema three years before starting latanoprost therapy. CONCLUSIONS: These findings suggest that visually significant cystoid macular edema associated with latanoprost therapy in pseudophakic or aphakic patients is uncommon. If there is a cause-and-effect relationship between latanoprost therapy and clinically significant cystoid macular edema, the incidence appears to be low.
Dr. M.B. Shields, Yale Eye Center, 330 Cedar Street, New Haven, CT 06520, USA
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
